Who is sponsoring NCT03511755?

NCT03511755 is sponsored by Thync Global, Inc..

What drugs are being tested in NCT03511755?

Interventions in NCT03511755: Transdermal Electrical Neuromodulator (TEN).

What condition does NCT03511755 study?

NCT03511755 studies Psoriasis, Stress.

Is NCT03511755 still recruiting?

NCT03511755 is currently completed. Last updated 21 August 2018.

Last reviewed 2018-08-21 · How we verify

NCT03511755

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

12-Week Study Assessing Change in Psoriasis Severity and Level of Stress Using TEN

Completed NA Last updated 21 August 2018

What this trial tests

NA trial testing Transdermal Electrical Neuromodulator (TEN) in Psoriasis in 36 participants. Completed in 24 July 2018.

Timeline

12 March 2018

Primary endpoint
24 July 2018

24 July 2018

Quick facts

Lead sponsor	Thync Global, Inc.
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	36
Start date	12 March 2018
Primary completion	24 July 2018
Estimated completion	24 July 2018
Sites	3 locations across United States

Drugs / interventions tested

Transdermal Electrical Neuromodulator (TEN)

Conditions studied

Psoriasis — all drugs for Psoriasis →
Stress — all drugs for Stress →

Sponsor

Thync Global, Inc.

Who can join

18 and older, any sex, with Psoriasis or Stress. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a 12-Week, multicenter, double-blind, controlled, randomized study assessing change in psoriasis severity and level of stress in patients with moderate to severe psoriasis treated with TEN. Psoriasis severity and stress levels will be measured at Weeks 0, 4, 8 and 12.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Psoriasis

Currently open trials in the same condition.

NCT07471048 — A Study to Evaluate the Impact of a Magnolia Officinalis Dietary Supplement on Immune Biomarkers in Subjects With Psoria · NA · recruiting
NCT07449234 — A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis · recruiting
NCT07234838 — Effect of Anti-Psoriatic Biologics on Risk of Anogenital Warts (CONDYPSO) · recruiting
NCT07194200 — Safety and Efficacy of Lactobacillus Plantarum for Psoriasis: A Randomized Double-Blind Placebo-Controlled Trial · Phase 2 · recruiting
NCT07250997 — PALLAS Laser for Skin Diseases · NA · recruiting

Other Thync Global, Inc. trials

Trials by the same sponsor.

NCT03817164 — Efficacy and Safety Study of Autonomic Nerve Modulation (ANM) in Subjects With Moderate Plaque Psoriasis · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03511755 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Thync Global, Inc.
Last refreshed: 21 August 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03511755.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing